Whether you can enjoy healthy ageing depends on where you live

Publicly released:
Australia; International; NSW
CC-0. https://unsplash.com/photos/person-holding-white-ceramic-teacup-L30rgHYSyuU
CC-0. https://unsplash.com/photos/person-holding-white-ceramic-teacup-L30rgHYSyuU

International scientists analysed healthy ageing in 40 countries across four continents, including a total of more than 160,000 people, and found big differences between them. Whether we age healthily is affected by a lot of different factors throughout life, collectively termed the 'exposome' by researchers. The team investigated the exposome and people's health in Europe, Latin America, Asia, and Africa, finding that 'accelerated ageing' was most common in less wealthy countries, such as Egypt and South Africa, whereas European countries, such as Germany, France and Italy, had higher rates of healthy ageing. The team found that people with accelerated ageing were eight times more likely to have reduced capacity to do daily tasks and four times more likely to experience cognitive decline, compared with people who were ageing more slowly. They also identified some key factors in the exposome that appear to play a role in healthy ageing, including air quality, and socioeconomic and gender equality, as well as sociopolitical factors, such as political representation, party freedom, suffrage and democratic elections.

Media release

From: Springer Nature

Assessing the factors behind global disparities in healthy ageing

Differences in physical, social, and sociopolitical factors across the world have resulted in marked disparities in healthy ageing across countries — according to an analysis of over 160,000 participants from 40 countries, published in Nature Medicine. The findings highlight the need for targeted interventions and policy actions to address health disparities, particularly in lower-income countries.

Healthy ageing is a complex biological process shaped by a number of factors experienced throughout life — collectively known as the exposome. Previous research has shown that the exposome has a much greater impact on healthy ageing than chronological age alone. However, understanding how these exposomal factors affect ageing across different populations and diverse regions has remained elusive.

Agustin Ibanez and colleagues examined how exposomal factors influence healthy and accelerated ageing across diverse populations using cohorts representing 40 countries in 4 continents (including Europe, Latin America, Asia, and Africa). They found that people experiencing accelerated ageing — defined by the difference between estimated biological age and chronological age — were eight times more likely to have reduced capacity to do daily tasks (functional ability) and four times more likely to experience cognitive decline than those undergoing delayed ageing. Accelerated ageing was most pronounced in lower-income countries, such as Egypt and South Africa, followed by countries in Asia and Latin America, whereas European countries, such as Germany, France and Italy, exhibited higher rates of healthy ageing.

When analyzing exposomal influences, the authors identified several key predictors of healthy ageing at the country level. These included physical factors, such as air quality; social factors, including socioeconomic and gender equality; and sociopolitical factors, such as political representation, party freedom, suffrage and democratic elections. These findings highlight how different environmental, social and political contexts collectively shape ageing outcomes across populations from different countries.

The authors argue that with increasing trends in dementia and accelerated ageing, reducing modifiable risks, strengthening protective factors and addressing inequalities are crucial for global public health at the population level. However, they emphasize that their findings reflect associations rather definitive causal relationships, and that the research features limited representation of certain regional populations — especially Africa.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends
Journal/
conference:
Nature Medicine
Research:Paper
Organisation/s: The University of Sydney, Trinity College Dublin, Ireland
Funder: H.H. is supported by Davos Alzheimer’s collaborative. A.I. is supported by grants from the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat, supported by Fogarty International Center (FIC), National Institutes of Health, National Institutes of Aging (R01 AG057234, R01 AG075775, R01 AG21051, R01 AG083799, CARDS-NIH), Alzheimer’s Association (SG-20-725707), Rainwater Charitable Foundation—The Bluefield Project to Cure FTD, and Global Brain Health Institute), ANID/FONDECYT Regular (1210195 and 1210176 and 1220995), ANID/PIA/ANILLOS ACT210096, FONDEF ID20I10152 and ANID/FONDAP 15150012. F.R.F. is supported by Alzheimer’s Association Fellowship (AARF-21-848281). C.D.-A. is supported by ANID/FONDECYT Regular 1210622, ANID/PIA/ANILLOS ACT210096, Alzheimer’s Association (AARGD-24- 1310017), ANID/FOVI240065 and ANID/Proyecto Exploración 13240170. J. Cruzat is supported by ANID (FONDECYT Postdoctorado number 3240042). H.S.-G. is supported by NIH R01 (Social Epigenetics of Alzheimer’s Disease and Related Dementias in Latin American Countries, number: 1R01AG082056- 01A1), Global Brain Health Institute and Alzheimer Association (‘Brain Health in Individuals with Exposition to High Violence in Colombia’, number: GBHI ALZ UK-23-971135). In addition, research reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW012455. J.J.M. acknowledges having received support from the Alliance for Health Policy and Systems Research (2009/32034, 2012/253750), Bloomberg Philanthropies (grant 46129, via University of North Carolina at Chapel Hill School of Public Health), FONDECYT via CIENCIACTIVA/CONCYTEC, British Council, British Embassy and the Newton–Paulet Fund (223-2018, 224-2018), DFID/MRC/Wellcome Global Health Trials (MR/M007405/1), Fogarty International Center (R21TW009982, D71TW010877, R21TW011740, K01TW011478), Grand Challenges Canada (GMH-POC-0335-04), International Development Research Center Canada (IDRC 106887, 108167), Inter-American Institute for Global Change Research (IAI CRN3036), National Cancer Institute (NCI 1P20CA217231), National Council for Scientific and Technological Development (CNPq Brasil 408523/2023-9), National Health and Medical Research Council (NHMRC 2022566), National Heart, Lung and Blood Institute (NHLBI HHSN268200900033C, 5U01HL114180, 1UM1HL134590), National Institute for Health and Care Research (NIHR 150261, NIHR 150287), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK K23DK135798), National Institute of Mental Health (NIMH 1U19MH098780), NSW Health, Cardiovascular Elite Postdoctoral Researcher Grants (H23/37663), Swiss National Science Foundation (40P740-160366), UKRI BBSRC (BB/T009004/1), UKRI EPSRC (EP/V043102/1), UKRI MRC (MR/P008984/1, MR/P024408/1, MR/P02386X/1, MR/X004163/1, MR/X020851/1), Wellcome (074833/Z/04/Z, 093541/Z/10/Z, 103994/Z/14/Z, 107435/Z/15/Z, 205177/Z/16/Z, 214185/Z/18/Z, 218743/Z/19/Z), World Diabetes Foundation (WDF15-1224) and the World Health Organization (2021/1189041, 2022/1249357). J.M. is supported by postdoctoral fellowships granted by the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat) and the Atlantic Fellows for Equity in Brain Health program. Although not directly funding this work, CU receives research funding support from The UKRI Medical Research Council (MR/Y019822/1), Alzheimer’s Association (SAGA23-1141999), The Wellcome Leap Dynamic resilience program (co-funded by Temasek Trust), National Institute of Health (NIH) (RO1-AG074562), Office for Veterans’ Affairs UK Defense and Security Accelerator (DASA) Fund (G2-SCH-2022-11-12245), Global Brain Health Institute (UFRA-424|CA-0241758), Davos Alzheimer’s Collaborative Global Cohorts Fund and RoseTrees Foundation (Seedcorn2021\100220). S.B. is supported by Global Brain Health Institute, Alzheimer’s Association, Alzheimer’s Society UK, Pilot Awards for Global Brain Health Leaders (Grant Number: GBHI ALZ UK- 25- 1289623).
Media Contact/s
Contact details are only visible to registered journalists.